ArticleCureus2026
Complex Challenges in ANCA-Associated Vasculitis: A Case of COVID-19, Cytomegalovirus Pneumonitis, and Hemorrhagic Cholecystitis Following Rituximab Therapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a rare autoimmune disease with significant infectious and hemorrhagic risks during immunosuppressive therapy. We describe an 81-year-old woman with perinuclear ANCA (p-ANCA)-associated vasculitis complicated by acute respiratory distress syndrome from concurrent COVID-19 and CMV pneumonitis following rituximab induction. Her course was further complicated by hemorrhagic cholecystitis, a rare bleeding manifestation, requiring percutaneous intervention. Careful adjustment of immunosuppression was necessary due to severe infections. This case highlights the complexity of managing AAV amid severe infections and rare hemorrhagic complications, emphasizing the need for vigilant monitoring and individualized therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.